P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In

 

 

 

 

 

Positive Data Reported for Subcutaneous Ofatumumab in Multiple Sclerosis

Treatment reduces number of brain lesions in phase II trial (October 10)

Positive results have been reported from a phase II study of a subcutaneous formulation of ofatumumab (Genmab) in relapsing-remitting multiple sclerosis (RRMS).

A total of 232 subjects with RRMS were enrolled in the study. There was a clear separation from placebo on the cumulative number of new gadolinium-enhancing lesions (active brain lesions) over a period of 12 weeks in subjects treated with all doses of ofatumumab compared with subjects treated with placebo (P < 0.001).

The study’s primary objective was to determine whether 3 mg, 30 mg, or 60 mg of subcutaneous ofatumumab can reduce the number of new T1-weighted gadolinium-enhancing brain lesions over 12 weeks compared with placebo in subjects with RRMS. For this endpoint, an analysis of data from weeks 0 to 12 estimated a 65% reduction in the cumulative number of new T1 gadolinium-enhancing lesions for all doses (P < 0.001). From weeks 4 to 12, analyses of data estimated a reduction of 90% or more in the cumulative number of new T1 gadolinium-enhancing lesions for all cumulative doses of ofatumumab of 30 mg or more (P < 0.001).

From weeks 0 to 12, injection-related reactions were the most common adverse events (AEs) and were observed in 52% of subjects receiving ofatumumab compared with 15% of subjects receiving placebo. Five serious AEs were reported; all of these subjects received a 60-mg dose of ofatumumab, and none of the subjects withdrew from the study.

Source: Genmab; October 11, 2013.

More stories